Revenue
5.12 billion USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 5115800000 USD Source
Fundies. English
REGENERON PHARMACEUTICALS, INC.
EDGARAnnual consolidated revenue for 2025: about USD 14.34B, using the latest reported figures. The previous period, 2024, was about USD 14.2B.
Latest quarter
Operating margin
40.04%
2026 Q3 · %
Operating cash flow
1.78 billion USD
2026 Q3 · USD
- Cash and cash equivalents
- 3.66 billion USD Source
Exact value
3659100000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- Not available
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
16.9 billion USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
Net income
4.82 billion USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
Operating cash flow
4.85 billion USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
- Operating cash flow: 4978900000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: 3808200000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: 1078900000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 1891900000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: 1078900000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 3675300000 USD · 2026-01-01 – 2026-09-30 Source
- Operating cash flow: 1891900000 USD · 2026-01-01 – 2026-06-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 11 of 11 periods available· newest 2025-12-31
- Operating income: 11 of 11 periods available· newest 2025-12-31
- Net income: 11 of 11 periods available· newest 2025-12-31
- Operating cash flow: 11 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 11 of 11 periods available· newest 2025-12-31
- Total liabilities: 11 of 11 periods available· newest 2025-12-31
- Current assets: 11 of 11 periods available· newest 2025-12-31
- Current liabilities: 11 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+1%Prior period
USD 14.2 billion
–
Current period
USD 14.34 billion
–
Exact inputs and evidence
14342900000 − 14202000000 = 140900000 USD
14202000000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source14342900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+2.1%Prior period
USD 4.41 billion
–
Current period
USD 4.5 billion
–
Exact inputs and evidence
4504900000 − 4412600000 = 92300000 USD
4412600000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source4504900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+12.6%Prior period
USD 4.42 billion
–
Current period
USD 4.98 billion
–
Exact inputs and evidence
4978900000 − 4420500000 = 558400000 USD
4420500000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source4978900000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 14.34 billion 100% of revenue
- Operating costs Derived USD 10.77 billion 75% of revenue
- Operating income USD 3.58 billion 25% of revenue
- Tax, interest and other Derived −USD 927 million −6.5% of revenue
- Net income USD 4.5 billion 31% of revenue
Cash
- Operating cash flow USD 4.98 billion 35% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2016 18%73%
- 2017 20%15%65%
- 2018 48%51%
- 2019 32%66%
- 2020 41%58%
- 2021 50%44%
- 2022 36%61%
- 2023 30%69%
- 2024 Net income was higher than operating income, so the split is not drawn.
- 2025 Net income was higher than operating income, so the split is not drawn.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | 4860400000 | 3529700000 Derived | 1330700000 | 435200000 Derived | 895500000 | Unavailable | Source
|
| 2017 2017-01-01 – 2017-12-31 | 5872200000 | 3792600000 Derived | 2079600000 | 881100000 Derived | 1198500000 | Unavailable | Source
|
| 2018 2018-01-01 – 2018-12-31 | 5145600000 | 2611200000 Derived | 2534400000 | 90000000 Derived | 2444400000 | Unavailable | Source
|
| 2019 2019-01-01 – 2019-12-31 | 6557600000 | 4347800000 Derived | 2209800000 | 94000000 Derived | 2115800000 | Unavailable | Source
|
| 2020 2020-01-01 – 2020-12-31 | 8497100000 | 4920500000 Derived | 3576600000 | 63400000 Derived | 3513200000 | Unavailable | Source
|
| 2021 2021-01-01 – 2021-12-31 | 16071700000 | 7124900000 Derived | 8946800000 | 871500000 Derived | 8075300000 | Unavailable | Source
|
| 2022 2022-01-01 – 2022-12-31 | 12172900000 | 7434000000 Derived | 4738900000 | 400500000 Derived | 4338400000 | Unavailable | Source
|
| 2023 2023-01-01 – 2023-12-31 | 13117200000 | 9070100000 Derived | 4047100000 | 93500000 Derived | 3953600000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 14202000000 | 10211300000 Derived | 3990700000 | -421900000 Derived | 4412600000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 14342900000 | 10765000000 Derived | 3577900000 | -927000000 Derived | 4504900000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 14.3B 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Revenue | 4860400000 |
|
| 2017 | Revenue | 5872200000 |
|
| 2018 | Revenue | 5145600000 |
|
| 2019 | Revenue | 6557600000 |
|
| 2020 | Revenue | 8497100000 |
|
| 2021 | Revenue | 16071700000 |
|
| 2022 | Revenue | 12172900000 |
|
| 2023 | Revenue | 13117200000 |
|
| 2024 | Revenue | 14202000000 |
|
| 2025 | Revenue | 14342900000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
1% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Year over year | 18.4% |
|
| 2017 | Year over year | 20.8% |
|
| 2018 | Year over year | -12.4% |
|
| 2019 | Year over year | 27.4% |
|
| 2020 | Year over year | 29.6% |
|
| 2021 | Year over year | 89.1% |
|
| 2022 | Year over year | -24.3% |
|
| 2023 | Year over year | 7.8% |
|
| 2024 | Year over year | 8.3% |
|
| 2025 | Year over year | 1% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin 24.9% 2025
Net margin 31.4% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Operating margin | 27.4% |
|
| 2017 | Operating margin | 35.4% |
|
| 2018 | Operating margin | 49.3% |
|
| 2019 | Operating margin | 33.7% |
|
| 2020 | Operating margin | 42.1% |
|
| 2021 | Operating margin | 55.7% |
|
| 2022 | Operating margin | 38.9% |
|
| 2023 | Operating margin | 30.9% |
|
| 2024 | Operating margin | 28.1% |
|
| 2025 | Operating margin | 24.9% |
|
| 2016 | Net margin | 18.4% |
|
| 2017 | Net margin | 20.4% |
|
| 2018 | Net margin | 47.5% |
|
| 2019 | Net margin | 32.3% |
|
| 2020 | Net margin | 41.3% |
|
| 2021 | Net margin | 50.2% |
|
| 2022 | Net margin | 35.6% |
|
| 2023 | Net margin | 30.1% |
|
| 2024 | Net margin | 31.1% |
|
| 2025 | Net margin | 31.4% |
|
| 2016 | Free cash flow margin | Not reported |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | Not reported |
|
| 2019 | Free cash flow margin | Not reported |
|
| 2020 | Free cash flow margin | Not reported |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD 5B 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Operating cash flow | 1485900000 |
|
| 2017 | Operating cash flow | 1307100000 |
|
| 2018 | Operating cash flow | 2195100000 |
|
| 2019 | Operating cash flow | 2430000000 |
|
| 2020 | Operating cash flow | 2618100000 |
|
| 2021 | Operating cash flow | 7081300000 |
|
| 2022 | Operating cash flow | 5014900000 |
|
| 2023 | Operating cash flow | 4594000000 |
|
| 2024 | Operating cash flow | 4420500000 |
|
| 2025 | Operating cash flow | 4978900000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Free cash flow | Unavailable |
|
| 2017 | Free cash flow | Unavailable |
|
| 2018 | Free cash flow | Unavailable |
|
| 2019 | Free cash flow | Unavailable |
|
| 2020 | Free cash flow | Unavailable |
|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
22.9% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Liabilities / assets | 36.2% |
|
| 2017 | Liabilities / assets | 29.9% |
|
| 2018 | Liabilities / assets | 25.4% |
|
| 2019 | Liabilities / assets | 25.1% |
|
| 2020 | Liabilities / assets | 35.8% |
|
| 2021 | Liabilities / assets | 26.2% |
|
| 2022 | Liabilities / assets | 22.4% |
|
| 2023 | Liabilities / assets | 21.5% |
|
| 2024 | Liabilities / assets | 22.3% |
|
| 2025 | Liabilities / assets | 22.9% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
4.13× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Current assets / current liabilities | 2.56× |
|
| 2017 | Current assets / current liabilities | 3.82× |
|
| 2018 | Current assets / current liabilities | 4.47× |
|
| 2019 | Current assets / current liabilities | 3.67× |
|
| 2020 | Current assets / current liabilities | 3.63× |
|
| 2021 | Current assets / current liabilities | 3.56× |
|
| 2022 | Current assets / current liabilities | 5.06× |
|
| 2023 | Current assets / current liabilities | 5.69× |
|
| 2024 | Current assets / current liabilities | 4.73× |
|
| 2025 | Current assets / current liabilities | 4.13× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | USD 895.5 million Exact valueExact value: 895500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.49 billion Exact valueExact value: 1485900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | USD 1.2 billion Exact valueExact value: 1198500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.31 billion Exact valueExact value: 1307100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | USD 2.44 billion Exact valueExact value: 2444400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.2 billion Exact valueExact value: 2195100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | USD 2.12 billion Exact valueExact value: 2115800000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.43 billion Exact valueExact value: 2430000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | USD 3.51 billion Exact valueExact value: 3513200000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2.62 billion Exact valueExact value: 2618100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | USD 8.08 billion Exact valueExact value: 8075300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 7.08 billion Exact valueExact value: 7081300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | USD 4.34 billion Exact valueExact value: 4338400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 5.01 billion Exact valueExact value: 5014900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | USD 3.95 billion Exact valueExact value: 3953600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 4.59 billion Exact valueExact value: 4594000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | USD 4.41 billion Exact valueExact value: 4412600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 4.42 billion Exact valueExact value: 4420500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | USD 4.5 billion Exact valueExact value: 4504900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 4.98 billion Exact valueExact value: 4978900000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
223 filings · 5,414 latest values · 5,414 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000872589, 872589, REGN, edgar:872589
Also known as REGENERON PHARMACEUTICALS INC, REGENERON PHARMACEUTICALS, INC.